Genmab A/S High Paying Jobs, Compensation Information and Expert Network Connections

Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark - internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. It's a dual listed company with shares traded on the Copenhagen Stock Exchange in Denmark, and on NASDAQ Global Select Market in the US.

The company has 3 approved antibodies used in 5 marketed products, covering cancer indications and autoimmune diseases:

Futhermore daratumumab is in clinical development for Non-MM blood cancers, and teprotumumab is in clinical development for diffuse cutaneous systemic sclerosis.

Besides these 3 antibodies the company has a broad clinical and pre-clinical pipeline of antibody products.